Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2020 Earnings Conference Call February 25, 2021 8:00 AM ET Company Participants Josh Rappaport - Investor Relations John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientist Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Rick Bienkowski - SVB Leerink Timur Ivannikov - Raymond James Joon Lee - Truist Securities Yanan Zhu - Wells Fargo Tashdid Hasan - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation o ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2020 Results Earnings Conference Call November 5, 2020 8:00 AM ET Company Participants Lina Li - Associate Director, IR John Leonard - President and Chief Executive Officer Laura Sepp-Lorenzino - Executive Vice President and Chief Scientific Officer Glenn Goddard - Executive Vice President, Chief Financial Officer David Lebwohl - Executive Vice President and Chief Medical Officer Conference Call Participants Salveen Richter - Goldman Sachs Maury Raycroft - Jeffer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 (State or Other Jurisdict ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 (State or Other Jurisdiction o ...

Intellia Therapeutics (NASDAQ:NTLA) Q2 2020 Earnings Conference Call August 5, 2020 8:00 AM ET Company Participants Lina Li - Associate Director, IR John Leonard - President, CEO & Director Laura Sepp-Lorenzino - EVP & Chief Scientific Officer Glenn Goddard - EVP & CFO Conference Call Participants Maurice Raycroft - Jefferies Xiaochuan Dai - Barclays Bank Madhu Kumar - Robert W. Baird & Co. Timur Ivannikov - Raymond James & Associates Jay Olson - Oppenheimer Operator Good morning. My name is Rachel, and I w ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Lina Li - Associate Director of Investor Relations John Leonard - Chief Executive Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Jos?? Rivera - General Counsel Conference Call Participants Timur Ivannikov - Raymond James Maury Raycroft - Jefferies Rick Bienkowski - SVB Leerink Madhu Kumar - R.W. Baird Tony Butler - ROTH Capital Jay Olson - Op ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 36-4785571 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139 (Address of Principal Executive Offices) (Zip Code) 857-285-6200 (Registrant's Telephone Number, Including Area Code) For the quarterly period ended March 31, 202 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation o ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2019 Earnings Conference Call February 27, 2020 8:00 AM ET Company Participants Lina Li - Associate Director, IR John Leonard - President, CEO & Director Laura Sepp-Lorenzino - EVP & Chief Scientific Officer Glenn Goddard - EVP & CFO Conference Call Participants Maurice Raycroft - Jefferies David Allen - Barclays Mani Foroohar - SVB Leerink Madhu Kumar - Robert W. Baird & Co. Steven Seedhouse - Raymond James & Associates Max Smock - BTIG Silvan Tuerkcan - Oppenhe ...